CagriSema Finally Beats Tirzepatide Head-to-Head — But Only vs the 5 mg Dose; FDA Decision Due Q4 2026

CagriSema Finally Beats Tirzepatide Head-to-Head — But Only vs the 5 mg Dose; FDA Decision Due Q4 2026

At its September 21, 2026 Capital Markets Day, Novo Nordisk (NYSE: NVO) unveiled Phase 3 topline data positioning once-weekly CagriSema (cagrilintide 1.0 mg + semaglutide 1.0 mg) as superior to Eli Lilly's (LLY) tirzepatide on weight loss for the first time — with important caveats about the comparator dose.

REIMAGINE 5 (type 2 diabetes, week 60): CagriSema achieved 12.4% weight loss vs 9.1% for tirzepatide 5 mg — the primary weight-loss superiority endpoint — while delivering a non-inferior HbA1c reduction of 1.71% vs 1.67%. Per the company's release (StockTitan): "once-weekly CagriSema 1.0 mg/1.0 mg achieved 12.4% weight loss versus 9.1% with tirzepatide 5 mg at week 60 in adults with type 2 diabetes in the REIMAGINE 5 trial."

REDEFINE 9 (obesity, week 68): CagriSema produced 21.0% weight loss vs 2.0% for placebo, meeting its primary superiority endpoint, with greater improvements than placebo in systolic blood pressure, waist-to-height ratio, and fasting lipids.

The caveats that matter for the competitive story:

1. The REIMAGINE 5 comparator was tirzepatide 5 mg — the lowest maintenance dose of Zepbound/Mounjaro, not the 15 mg max dose. In the earlier head-to-head (reported February 23, 2026), "Novo's next-gen obesity shot fails to match Lilly drug in head-to-head study" (BioPharma Dive) — i.e., CagriSema lost to full-dose tirzepatide. Novo's marketing framing of "superior weight loss versus tirzepatide" leans on the low-dose win.
2. The 21.0% REDEFINE 9 figure is vs placebo, not an active comparator; prior REDEFINE readouts vs placebo have landed below expectations before.
3. The 12.4% T2D figure trails the ~15-21% numbers that define the injectable obesity race, and T2D populations consistently lose less weight.

Regulatory status: Novo filed the CagriSema NDA for weight management in December 2025, with a US FDA decision expected in Q4 2026. A CagriSema approval would give Novo its first genuinely differentiated post-Wegovy injectable ahead of the 2027 launch year, but Lilly's Zepbound holds a ~60%+ obesity market share and a 2:1 GLP-1 sales lead (see Novo's Slide Deepens Post-CMD: Stock -21.4% in a Month, RSI 21, Trading at 9.4x Earnings).

Meaning: REIMAGINE 5 gives Novo a legitimate marketing claim — the first head-to-head weight-loss win over tirzepatide anywhere in the REDEFINE/REIMAGINE program — but the 5 mg comparator keeps the "CagriSema vs Zepbound at full dose" question unresolved, and that debate now runs straight into the Q4 2026 FDA decision.